Table 4.

The Clinical Indicators before and after SGLT2 Inhibitor Treatment.

	Before	3 months	p	6 months	p	n
HbA1c (%)	7.52 ± 1.16	7.02 ± 0.92	<0.001	6.95 ± 0.98	<0.001	111
Body weight (kg)	78.0 ± 15.3	76.2 ± 15.7	<0.001	75.6 ± 15.1	<0.001	110
BMI (kg/m2)	28.9 ± 4.7	28.2 ± 4.7	<0.001	28.0 ± 4.6	<0.001	110
Abdominal circumference (cm)	98.3 ± 10.5	96.5 ± 10.5	0.002	94.9 ± 10.3	<0.001	57
Visceral fat area (cm2)	108.4 ± 44.6	100.1 ± 40.9	<0.001	94.5 ± 45.3	<0.001	64
Subcutaneous fat area (cm2)	258.3 ± 80.0	241.9 ± 75.9	<0.001	229.2 ± 78.0	<0.001	64
Systolic blood pressure (mmHg)	133.7 ± 15.5	128.0 ± 14.6	<0.001	127.4 ± 13.5	<0.001	111
Diastolic blood pressure (mmHg)	79.6 ± 10.27	77.1 ± 9.4	0.007	75.2 ± 10.4	<0.001	111
AST (IU/L)	27.7 ± 15.6	23.9 ± 11.8	<0.001	23.1 ± 11.8	0.001	106
ALT (IU/L)	39.5 ± 31.2	32.9 ± 24.2	0.001	30.7 ± 22.7	<0.001	107
γGTP (IU/L)	53.1 ± 46.2	43.7 ± 33.5	<0.001	41.6 ± 34.1	<0.001	105
BUN (mg/dL)	14.5 ± 3.6	15.2 ± 4.1	0.051	14.9 ± 3.4	0.194	104
Uric acid (mg/dL)	5.3 ± 1.3	4.9 ± 1.3	0.002	4.8 ± 1.3	<0.001	86
Cr (mg/dL)	0.65 ± 0.15	0.68 ± 0.17	0.002	0.68 ± 0.15	<0.001	106
eGFR (mL/min/1.73m2)	93.1 ± 20.4	89.6 ± 21.0	0.010	88.7 ± 19.9	<0.001	106
Urinary albumin/creatinine ratio (mg/gCr)	82.1 ± 227.9	62.4 ± 203.1	<0.001	55.5 ± 148.8	0.079	101
LDL-C (mg/dL)	107.1 ± 29.7	106.0 ± 29.1	0.643	108.4 ± 32.1	0.629	106
HDL-C (mg/dL)	50.7 ± 14.8	51.7 ± 15.9	0.296	51.5 ± 14.9	0.329	107
Triglyceride (mg/dL)	228.6 ± 176.8	202.0 ± 129.5	0.061	201.2 ± 125.3	0.056	107

The values are expressed as the mean ± SD. HbA1c: glycated hemoglobin, BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, γ-GTP: γ-glutamyl transferase, BUN: blood urea nitrogen, Cr: creatinine, eGFR: estimated glomerular filtration rate, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol